Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Carcinoma|Breast Cancer
Interventions: DRUG: AZD2281
Sponsor: AstraZeneca
Collaborators: British Columbia Cancer Agency